NVAX · Novavax

The thesis

Novavax's third-quarter report beat estimates and lifted its 2026 revenue framework, but the shares have the gain, and the call is that they are more likely to lag the S&P 500 than lead it over the next three months. The raise is mostly the $125 million Sanofi milestone the market already knew about. The next payments depend on Sanofi's 2027 steps.

Novavax reported on 5 November 2026 that third-quarter revenue was $68 million, down 3% from $70 million a year earlier. Product sales rose 91% to $26 million. Benzinga's estimate comparison put sales at $68.298 million against a $50.430 million estimate, and the loss at $0.19 a share against $0.36 expected. The net loss narrowed to $31 million from $202 million, according to the company's results release.

The company raised its 2026 "adjusted total revenue" framework to $385–415 million from $235–275 million set on 6 August 2026. That measure excludes Sanofi supply sales, Sanofi royalties and future Sanofi milestones. The new range includes the $125 million milestone, which the company says was earned in October and so sits outside the September quarter and its cash balance. Benzinga listed the consensus estimate at $380.285 million before the report.

The market had already priced much of this. The shares closed at $10.65 on 4 November 2026 and at $9.78 on 5 November 2026, the day of the report. They closed at $9.98 on 11 November 2026, under the 50-day average of $10.6.

Bullish and bearish views on Novavax, Inc.

The bull case on Novavax, Inc. (NVAX), in brief: the guidance raise is large. The bear case: the raise is mostly known money.

Bull case

• The guidance raise is large. Novavax lifted the midpoint of its 2026 adjusted revenue framework by $145 million, to $400 million, on 5 November 2026. The company also narrowed its combined research and administrative expense guide to $375–395 million from $370–410 million.
• Results beat estimates. Benzinga reported third-quarter sales of $68.298 million against a $50.430 million estimate, and a loss of $0.19 a share against $0.36 expected, on 5 November 2026. Product sales of $26 million were up 91% from a year earlier, per the company's release.
• Costs are being cut hard. Novavax said on 5 November 2026 that it is exploring a reduction of more than 50% in its operating footprint through consolidating buildings and laboratories. It targets combined non-GAAP research and administrative spending of $150–200 million by 2028, according to the earnings call summary published by MarketBeat on 6 November 2026.
• Cash runway extends into 2029. The company reported $627 million in cash, equivalents, marketable securities and restricted cash at 30 September 2026, and $676 million including accounts receivable. Management said on the call that the runway extends into 2029, helped by the $125 million milestone and the expected $75 million technology-transfer payment.
• At least one analyst stays positive. Benzinga reported on 6 November 2026 that B. Riley Securities reiterated Buy on Novavax, with a price target of $16.

Bear case

• The raise is mostly known money. The 5 November 2026 framework includes the $125 million milestone that Novavax announced on 29 October 2026. The shares closed at $10.65 on 4 November 2026 and $9.78 on 5 November 2026.
• The next payments sit in 2027 or later. The company expects the $75 million technology-transfer milestone around mid-2027. The $225 million milestone is payable on the first US commercial sale of a combination vaccine, after Sanofi completes US clinical and regulatory work. Novavax says Sanofi expects to start a US Phase 3 trial in 2027 and gives no launch date.
• Revenue quality is mixed. Licensing, royalties and other revenue fell 25% to $43 million in the third quarter, mainly because Sanofi research reimbursement fell $42 million, per the company's release. That figure includes $11 million of non-cash deferred royalty recognition.
• Profitability depends on one US launch. On the call, management tied non-GAAP profitability mainly to a potential US launch in 2029 that would trigger the $225 million payment, and the chief financial officer said Novavax lacks access to Sanofi's detailed plans, according to MarketBeat's call summary dated 6 November 2026.
• A large holder has been selling. Shah Capital's Schedule 13D/A filed 16 October 2026 shows 2.87 million shares sold on 5 October 2026 at an average of about $11.35. It shows 10.54 million shares (6.39%) remaining and no intent to influence control.

Price setup

Novavax closed at $9.98 on 11 November 2026. That is 25.4% below the 52-week intraday high of $13.38 set on 5 October 2026, and up 22.6% over three months from the $8.14 close of 13 August 2026. The 52-week closing low is $6.22, set on 20 November 2025.

The 50-day average stands at $10.6 and the 200-day average at $9.34, both as of the 11 November 2026 close. The shares closed below the first and above the second. Closes since the report ran $9.78 on 5 November 2026, $10.78 on 6 November 2026, $10.89 on 9 November 2026, $10.20 on 10 November 2026 and $9.98 on 11 November 2026. The rebound to $10.89 gave way over the next two sessions.

The October run came from headlines outside the company. Benzinga tied the 5 October 2026 jump of about 24% to a suspected plague case in Russia, citing possible short covering. It tied the 9 October 2026 rise to a New York Times report on a National Institutes of Health cancer-vaccine initiative, though Novavax has no cancer-vaccine program.

Catalysts ahead

• ~18 November 2026 (est.): Novavax appearance at the Jefferies London Healthcare Conference (company announced participation on 11 November 2026; date not confirmed). Management commentary on Sanofi timing, the cost program and cash receipt of the $125 million milestone could move the revenue outlook.
• ~February 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether 2026 adjusted revenue lands inside the $385–415 million framework and gives the first 2027 expense view.
• ~June 2027 (est.): Completion of the Nuvaxovid manufacturing technology transfer to Sanofi. Triggers the next contracted partner payment of $75 million; a slip pushes that income further out.
• ~June 2027 (est.): Sanofi start of a US Phase 3 combination-vaccine trial (company says during 2027). Sets the path to the $225 million US-launch milestone; a delay or extra studies would push it past 2029.

What would change the view

A daily close above $12.82, which sits just under the $13.38 intraday 52-week high of 5 October 2026 and would show the shares leading the S&P 500 again. A 2026 adjusted revenue framework raised above the current $415 million top end would also show that.

What it trades with

Novavax's business tracks Sanofi (SNY), which controls Nuvaxovid sales, the combination-vaccine trial timetable and the remaining milestones. Sanofi's vaccine commentary moves Novavax's revenue outlook directly.

In October, the shares also traded with other vaccine stocks on sector headlines. Benzinga grouped Novavax with Moderna (MRNA) and Vaxcyte (PCVX) on the 5 October 2026 plague reports, and with Moderna and BioNTech (BNTX) on the 9 October 2026 cancer-vaccine rally.